Ruthenium(II) Complex with 8-Hydroxyquinoline Exhibits Antitumor Activity in Breast Cancer Cell Lines
Cancers · 09.01.2025 · 17 (2) · 195
DOI: 10.3390/cancers17020195 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 09.01.2025. Verfasst von Amr Khalifa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Medical Specialties, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro (AIRC) to Alessio Nencioni, Funds to the Ospedale Policlinico San Martino IRCCS to Alessio Nencioni, Breast Cancer Research Program (US Department of Defense; to Alessio Nencioni).
Abstract (Originalsprache)
Background/Objectives: Breast cancer (BC) remains one of the most prevalent and deadly cancers worldwide, with limited access to advanced treatments in developing regions. There is a critical need for novel therapies with unique mechanisms of action, especially to overcome resistance to conventional platinum-based drugs. This study investigates the anticancer potential of the ruthenium complex Bis(quinolin-8-olato)bis(triphenylphosphine)ruthenium(II) (Ru(quin)2) in ER-positive (T47D) and triple-negative (MDA-MB-231) BC cell lines.
Results
Ru(quin)2 demonstrated dose-dependent cytotoxicity, with IC50 values of 48.3 μM in T47D cells and 45.5 μM in MDA-MB-231 cells. Its cytotoxic effects are primarily driven by apoptosis, as shown by increased BAX expression, enhanced caspase-3 activity, reduced Aurora B kinase levels, and elevated histone release. Ru(quin)2 also induced autophagy, evidenced by LC3-I to LC3-II conversion and reduced SQSTM1, partially mediated through MAPK signaling. Furthermore, Ru(quin)2 induced G0/G1 cell cycle arrest by downregulating cyclin D1, CDK4, and CDK6, alongside upregulation of the CDK inhibitor p21.
Conclusions
Ru(quin)2 emerges as a potent candidate for BC treatment, with multiple mechanisms of action involving apoptosis, autophagy, and cell cycle arrest. Further studies are warranted to elucidate its detailed molecular mechanisms and evaluate its therapeutic potential in vivo, moving toward clinical applications for both ER-positive and triple-negative BC management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine and Medical Specialties, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy.
- Department of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria P.O. Box 21526, Egypt.
- Department of Clinical Biochemistry, Faculty of Medicine, King Khalid University, Abha 62521, Saudi Arabia.
- Department of Chemistry, Faculty of Science, Alexandria University, Alexandria P.O. Box 21511, Egypt.
- Ospedale Policlinico San Martino IRCCS, Largo Rosanna Benzi 10, 16132 Genoa, Italy.
- Department of Biochemistry, Faculty of Science, Alexandria University, Alexandria P.O. Box 21511, Egypt.
ORCID-Profile: Amr Khalifa, Salah A Sheweita
Förderung
- Associazione Italiana per la Ricerca sul Cancro (AIRC) to Alessio Nencioni
- Funds to the Ospedale Policlinico San Martino IRCCS to Alessio Nencioni
- Breast Cancer Research Program (US Department of Defense; to Alessio Nencioni)
- Fondazione AIRC per la Ricerca sul Cancro
- Ospedale Policlinico San Martino IRCCS
Zitieren
APA
Khalifa, A., Sheweita, S. A., Namatalla, A., Khalifa, M. A., Nencioni, A., & Sultan, A. S. (2025). Ruthenium(II) Complex with 8-Hydroxyquinoline Exhibits Antitumor Activity in Breast Cancer Cell Lines. Cancers, 17(2), 195. https://doi.org/10.3390/cancers17020195
Vancouver
Khalifa A, Sheweita SA, Namatalla A, Khalifa MA, Nencioni A, Sultan AS. Ruthenium(II) Complex with 8-Hydroxyquinoline Exhibits Antitumor Activity in Breast Cancer Cell Lines. Cancers. 2025;17(2):195. doi:10.3390/cancers17020195
BibTeX
@article{Khalifa2025,
author = {Khalifa, Amr and Sheweita, Salah A and Namatalla, Asmaa and Khalifa, Mohamed A and Nencioni, Alessio and Sultan, Ahmed S},
title = {Ruthenium(II) Complex with 8-Hydroxyquinoline Exhibits Antitumor Activity in Breast Cancer Cell Lines},
journal = {Cancers},
year = {2025},
volume = {17},
number = {2},
pages = {195},
doi = {10.3390/cancers17020195}
}
EUVIMED